Allogeneic bone marrow transplantation for poor-prognosis lymphoma: Response, toxicity, and survival depend on disease histology

Koen W. Van Besien, Rakesh C. Mehra, Sergio A. Giralt, Hagop M. Kantarjian, William C. Pugh, Issa F. Khouri, Young Moon, Pat Williams, Borje S. Andersson, Donna Przepiorka, Philip L. McCarthy, James L. Gajewski, Albert B. Deisseroth, Fernando F. Cabanillas, Richard Champlin

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

PURPOSE: To evaluate outcomes and identify prognostic factors in allogeneic bone marrow transplantation in patients with end-stage lymphoma. PATIENTS AND METHODS: Data were retrospectively analyzed of 64 patients (42 men and 22 women) 18 to 48 years of age with recurrent or refractory lymphoma who underwent allogeneic bone marrow transplantation from matched sibling donors (or in 1 case from a one antigen-mismatched relative) between May 1981 and July 1994. RESULTS: Twelve patients survived free of disease. They were 8 of 15 with low-grade lymphoma (disease-free survival at 2 years 59% ± 13%); 3 of 25 with lymphoblastic lymphoma (disease-free survival 17% ± 8%); and 1 of 10 with diffuse small non-cleaved cell lymphoma (disease-free survival 10% ± 9%). Survival and disease-free survival of patients with low-grade lymphoma were significantly superior compared to any other subgroup of patients (P

Original languageEnglish (US)
Pages (from-to)299-307
Number of pages9
JournalAmerican Journal of Medicine
Volume100
Issue number3
DOIs
StatePublished - Mar 1996
Externally publishedYes

Fingerprint

Homologous Transplantation
Bone Marrow Transplantation
Lymphoma
Histology
Non-Hodgkin's Lymphoma
Disease-Free Survival
Survival
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Siblings
Tissue Donors
Antigens

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Van Besien, K. W., Mehra, R. C., Giralt, S. A., Kantarjian, H. M., Pugh, W. C., Khouri, I. F., ... Champlin, R. (1996). Allogeneic bone marrow transplantation for poor-prognosis lymphoma: Response, toxicity, and survival depend on disease histology. American Journal of Medicine, 100(3), 299-307. https://doi.org/10.1016/S0002-9343(97)89488-0

Allogeneic bone marrow transplantation for poor-prognosis lymphoma : Response, toxicity, and survival depend on disease histology. / Van Besien, Koen W.; Mehra, Rakesh C.; Giralt, Sergio A.; Kantarjian, Hagop M.; Pugh, William C.; Khouri, Issa F.; Moon, Young; Williams, Pat; Andersson, Borje S.; Przepiorka, Donna; McCarthy, Philip L.; Gajewski, James L.; Deisseroth, Albert B.; Cabanillas, Fernando F.; Champlin, Richard.

In: American Journal of Medicine, Vol. 100, No. 3, 03.1996, p. 299-307.

Research output: Contribution to journalArticle

Van Besien, KW, Mehra, RC, Giralt, SA, Kantarjian, HM, Pugh, WC, Khouri, IF, Moon, Y, Williams, P, Andersson, BS, Przepiorka, D, McCarthy, PL, Gajewski, JL, Deisseroth, AB, Cabanillas, FF & Champlin, R 1996, 'Allogeneic bone marrow transplantation for poor-prognosis lymphoma: Response, toxicity, and survival depend on disease histology', American Journal of Medicine, vol. 100, no. 3, pp. 299-307. https://doi.org/10.1016/S0002-9343(97)89488-0
Van Besien, Koen W. ; Mehra, Rakesh C. ; Giralt, Sergio A. ; Kantarjian, Hagop M. ; Pugh, William C. ; Khouri, Issa F. ; Moon, Young ; Williams, Pat ; Andersson, Borje S. ; Przepiorka, Donna ; McCarthy, Philip L. ; Gajewski, James L. ; Deisseroth, Albert B. ; Cabanillas, Fernando F. ; Champlin, Richard. / Allogeneic bone marrow transplantation for poor-prognosis lymphoma : Response, toxicity, and survival depend on disease histology. In: American Journal of Medicine. 1996 ; Vol. 100, No. 3. pp. 299-307.
@article{9219291abe9949ad855f028f9685b5d0,
title = "Allogeneic bone marrow transplantation for poor-prognosis lymphoma: Response, toxicity, and survival depend on disease histology",
abstract = "PURPOSE: To evaluate outcomes and identify prognostic factors in allogeneic bone marrow transplantation in patients with end-stage lymphoma. PATIENTS AND METHODS: Data were retrospectively analyzed of 64 patients (42 men and 22 women) 18 to 48 years of age with recurrent or refractory lymphoma who underwent allogeneic bone marrow transplantation from matched sibling donors (or in 1 case from a one antigen-mismatched relative) between May 1981 and July 1994. RESULTS: Twelve patients survived free of disease. They were 8 of 15 with low-grade lymphoma (disease-free survival at 2 years 59{\%} ± 13{\%}); 3 of 25 with lymphoblastic lymphoma (disease-free survival 17{\%} ± 8{\%}); and 1 of 10 with diffuse small non-cleaved cell lymphoma (disease-free survival 10{\%} ± 9{\%}). Survival and disease-free survival of patients with low-grade lymphoma were significantly superior compared to any other subgroup of patients (P",
author = "{Van Besien}, {Koen W.} and Mehra, {Rakesh C.} and Giralt, {Sergio A.} and Kantarjian, {Hagop M.} and Pugh, {William C.} and Khouri, {Issa F.} and Young Moon and Pat Williams and Andersson, {Borje S.} and Donna Przepiorka and McCarthy, {Philip L.} and Gajewski, {James L.} and Deisseroth, {Albert B.} and Cabanillas, {Fernando F.} and Richard Champlin",
year = "1996",
month = "3",
doi = "10.1016/S0002-9343(97)89488-0",
language = "English (US)",
volume = "100",
pages = "299--307",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Allogeneic bone marrow transplantation for poor-prognosis lymphoma

T2 - Response, toxicity, and survival depend on disease histology

AU - Van Besien, Koen W.

AU - Mehra, Rakesh C.

AU - Giralt, Sergio A.

AU - Kantarjian, Hagop M.

AU - Pugh, William C.

AU - Khouri, Issa F.

AU - Moon, Young

AU - Williams, Pat

AU - Andersson, Borje S.

AU - Przepiorka, Donna

AU - McCarthy, Philip L.

AU - Gajewski, James L.

AU - Deisseroth, Albert B.

AU - Cabanillas, Fernando F.

AU - Champlin, Richard

PY - 1996/3

Y1 - 1996/3

N2 - PURPOSE: To evaluate outcomes and identify prognostic factors in allogeneic bone marrow transplantation in patients with end-stage lymphoma. PATIENTS AND METHODS: Data were retrospectively analyzed of 64 patients (42 men and 22 women) 18 to 48 years of age with recurrent or refractory lymphoma who underwent allogeneic bone marrow transplantation from matched sibling donors (or in 1 case from a one antigen-mismatched relative) between May 1981 and July 1994. RESULTS: Twelve patients survived free of disease. They were 8 of 15 with low-grade lymphoma (disease-free survival at 2 years 59% ± 13%); 3 of 25 with lymphoblastic lymphoma (disease-free survival 17% ± 8%); and 1 of 10 with diffuse small non-cleaved cell lymphoma (disease-free survival 10% ± 9%). Survival and disease-free survival of patients with low-grade lymphoma were significantly superior compared to any other subgroup of patients (P

AB - PURPOSE: To evaluate outcomes and identify prognostic factors in allogeneic bone marrow transplantation in patients with end-stage lymphoma. PATIENTS AND METHODS: Data were retrospectively analyzed of 64 patients (42 men and 22 women) 18 to 48 years of age with recurrent or refractory lymphoma who underwent allogeneic bone marrow transplantation from matched sibling donors (or in 1 case from a one antigen-mismatched relative) between May 1981 and July 1994. RESULTS: Twelve patients survived free of disease. They were 8 of 15 with low-grade lymphoma (disease-free survival at 2 years 59% ± 13%); 3 of 25 with lymphoblastic lymphoma (disease-free survival 17% ± 8%); and 1 of 10 with diffuse small non-cleaved cell lymphoma (disease-free survival 10% ± 9%). Survival and disease-free survival of patients with low-grade lymphoma were significantly superior compared to any other subgroup of patients (P

UR - http://www.scopus.com/inward/record.url?scp=17944403263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17944403263&partnerID=8YFLogxK

U2 - 10.1016/S0002-9343(97)89488-0

DO - 10.1016/S0002-9343(97)89488-0

M3 - Article

C2 - 8629675

AN - SCOPUS:17944403263

VL - 100

SP - 299

EP - 307

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 3

ER -